News | July 04, 2023
Adare Pharma divests Adare Biome to dsm-firmenich
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The company is already marketing the 4 mg and 10 mg strengths
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Subscribe To Our Newsletter & Stay Updated
